Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
0.000000 Euro
Request Reference:
06/02598.11/2024 - Aq. de Obinutuzumab 25 mg/ml so
Request Name:
06/02598.11/2024 - Aquisição de Obinutuzumab 25 mg/ml Sol inj Fr 40 ml IV "GAZYVARO" AQ 2023/491
Phase:
Tendering Phase
State:
Awarded
Description:
06/02598.11/2024 - Aquisição de Obinutuzumab 25 mg/ml Sol inj Fr 40 ml IV "GAZYVARO" AQ 2023/491
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
O995 - OBINUTUZUMAB [25 MG/ML; 40 ML; SOL INJ; FRS]
-
6
(
Months
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Rua Dr. Cândido Pinho 4520 211 PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
6/28/2024 4:12 PM
(UTC +1 hour)
National official publishing date and time (DR):
9/4/2023 12:57 PM
(UTC +1 hour)
Due datetime for receiving replies:
7/2/2024 5:00 PM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Anexo III.xlsx
Anexo III.xlsx
Download
Convite e CE_0602598.112024.pdf
Convite e CE_0602598.112024.pdf
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
O995 - OBINUTUZUMAB [25 MG/ML; 40 ML; SOL INJ; FRS]
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
O995
OBINUTUZUMAB [25 MG/ML; 40 ML; SOL INJ; FRS]
6,000000
UNI
Buyer Comment:
500233810 | Roche - Farmacêutica Química, Lda. | CPA:2023491/150/0368 | NºAIM:5618954;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Manual
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - O995 - OBINUTUZUMAB [25 MG/ML; 40 ML; SOL INJ; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
Preço
100%
Normas de desempate
Definir normas de desempate?
Sim
Não
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...